level3trading

  First Wave BioPharma Scores Phase2b Milestone; First Patient Dosed Targeting Unmet Treatment For Ulcerative Proctitis And UPS (NASDAQ: FWBI) First Wave BioPharma (NASDAQ: FWBI) has reached another milestone, commencing its Phase2b trial evaluating topical niclosamide to treat ulcerative proctitis and ulcerative proctosigmoiditis. The news takes the FWBI value-proposition from excellent to compelling. Pre-market on Thursday, FWBI announced dosing the first patient in a Phase 2b clinical trial investigating a topical formulation of niclosamide (FW-UP) as a potential treatment for patients with ulcerative proctitis (UP) and ulcerative proctosigmoiditis (UPS). UP and UPS are two types of ulcerative colitis, a chronic inflammatory bowel disease (IBD) consisting of fine ulcerations in the inner mucosal lining of the large intestine that do not penetrate the bowel muscle wall. UPS causes inflammation in the colon and rectum, while UP is confined only to the rectum. Both are debilita...

Digital Brands Group, Inc. (NASDAQ: DBGI) stock continues to trend higher, increasing more than 8% higher since the start of last month. On Thursday, investors were provided at least one of the reasons for the impressive growth- a surge in e-commerce revenues. And not just a trivial amount. E-Commerce sales for its Bailey’s 44 apparel brand, for instance, surged by more than 376% year-over-year. That’s not all. The focus toward digital advertising also pushed revenues for its DSTLD line of apparel higher by more than 52% since October 10th of this year, which is when the digital ad program for that brand started. More specifically, DSTLD experienced a 24% increase in its average order volume and a 76% increase in new customers. The better news is that those results come after an $8,000 ad spend. According to DBGI, the budget for set until EOY 2021 is set at $300,000. That compares to ZERO from the year before. The results are equally impressive for Bailey’s 44, whose 376% revenue inc...